Advertisements

Ap Loratadine

Quick links to important sections

Ap Loratadine

Advertisements

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Ap Loratadine

Quick Facts

Property Description
Active ingredient Loratadine
Form Tablet, Syrup, Capsule (Oral)
Pharmacological class Antihistamine, Second-Generation
Common use Relief from Allergic Disorders
Origin Synthetic

What Type of Medicine is Loratadine?

Loratadine is the core active ingredient in Ap Loratadine, chemically synthesized and classified as an Antihistamine. It is formally designated as a second-generation antihistamine and functions as a selective peripheral H1-receptor antagonist. This classification reflects a compound designed to manage symptoms arising from allergic disorders by targeting the body's allergic response in the periphery. It provides relief from the generalized symptoms of allergy. Loratadine is typically available as a single-ingredient product, though it may be found in combination with decongestants.


Composition and General Purpose of Ap Loratadine

The overarching general purpose of Ap Loratadine is to provide long-acting systemic assistance in managing the discomfort and inflammatory burden associated with general allergies. The medication is prepared for oral administration and is supplied in several common oral dosage forms, including the familiar tablet, chewable tablet, oral solution (syrup), and the rapidly disintegrating tablet.

In its tablet form, the high-level composition consists of the Loratadine active ingredient alongside inert components, such as microcrystalline cellulose, which act as the solid base/vehicle to facilitate systemic absorption. The Ap prefix typically indicates a generic preparation associated with a specific manufacturer, ensuring chemical equivalence to the innovator product while maintaining the active ingredient's therapeutic profile.


Why is Loratadine Considered a Non-Sedating Antihistamine?

Loratadine is accurately described as non-sedating because its molecular design limits its ability to penetrate the central nervous system. This feature is the result of its high selectivity for peripheral H1-receptors rather than those in the brain, thereby minimizing the sedative effects commonly seen with older, first-generation antihistamines. This distinction is a key characteristic of the second-generation class, enabling patients to mitigate allergic discomfort without substantial impairment of daily cognitive function.

Regulatory References

  1. Loratadine - LiverTox (NCBI/NIH)
  2. Loratadine: MedlinePlus Drug Information (NIH)
  3. Loratadine Drug Facts - DailyMed (NIH/FDA)
Advertisements

What side effects are possible with Ap Loratadine?

Possible Side Effects and Safety Information

The safety profile of Ap Loratadine (Loratadine) is established through regulatory review of clinical trial data and post-marketing surveillance, classified by frequency and affected body system (System Organ Class or SOC).

Documented Adverse Reactions

Adverse reactions are officially classified as Common (observed in 1/100 to 1/10 patients) or Very Rare (observed in less than 1/10,000 patients, often from post-marketing reports).

Frequency Examples of Officially Listed Adverse Reactions System Organ Class
Common Headache, Somnolence (Drowsiness), Fatigue, Increased Appetite Nervous System, General Disorders, Metabolism
Very Rare Tachycardia, Palpitation, Dizziness, Convulsion, Nausea, Rash, Alopecia Cardiac, Nervous System, Gastrointestinal, Skin

Serious Adverse Reactions

Rare, but clinically significant, adverse events documented in regulatory information include severe Hypersensitivity Reactions (such as Anaphylaxis and Angioedema) and signs of serious Abnormal Hepatic Function (including Hepatitis, Jaundice, and Hepatic Necrosis).

Population-Specific Safety Statements

Official regulatory documents detail specific safety considerations for certain patient groups:

  • Severe Hepatic Impairment: Caution is advised, and a potential dose adjustment (e.g., 10 mg every other day) is recommended for adults and children over 30 kg with severe liver disease.
  • Pediatrics: Safety and effectiveness have not been established in children under two years of age.
  • Pregnancy and Lactation: Use during pregnancy is advised to be avoided as a precaution, and the drug is known to pass into breast milk.

Safety Restrictions

A mandated safety restriction is that Ap Loratadine should be discontinued for at least 48 hours prior to conducting any skin allergy tests, as the medicine can interfere with the test results.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information for Ap Loratadine

Official regulatory documents define the Loratadine overdose profile based on specific clinical manifestations and mandated emergency actions.

Category Official Regulatory Statement
Documented Manifestations Symptoms reported in overdose cases include somnolence (drowsiness), headache, and tachycardia (rapid heart rate). Overdosage may also increase the occurrence of anticholinergic symptoms.
Emergency Action Required Individuals who suspect an overdose must seek immediate medical help or contact a Poison Control Center right away. Emergency services must be called if the individual has collapsed, experienced a seizure, or cannot be awakened.
Supportive Treatment No specific antidote is known for Loratadine overdose. Management requires the prompt institution of general symptomatic and supportive measures. Procedural steps such as gastric lavage and administration of activated charcoal may be considered.
Monitoring Requirements Medical monitoring of the patient is required to be continued after emergency treatment, focusing on clinical observation. Overdoses in pediatric patients have also been reported to include specific signs such as Extrapyramidal signs and Palpitations.

The regulatory profile is structured around the explicit requirement to seek immediate professional medical attention due to the documented neurological and cardiovascular signals. This action is critical, given that treatment is purely supportive and requires continued clinical observation until stable.

Advertisements

Therapeutic Uses of Ap Loratadine

What Ap Loratadine Treats: Main Uses and Benefits

Ap Loratadine is commonly used for managing symptomatic relief across domains affected by allergic reactions. It is generally applied in contexts involving inflammatory or irritative states caused by allergens.

The medication is relevant for easing symptoms associated with specific conditions, including seasonal allergic rhinitis (hay fever), perennial allergic rhinitis, and chronic urticaria (hives). It is applied when symptoms may become intense or disruptive, such as frequent sneezing, a runny nose, and the discomfort from itchy or watery eyes, as well as skin-related itching and wheal formation.

“This supportive function may help patients cope more steadily with symptom fluctuations.”

It provides supportive relief when symptoms interfere with routine activities. It may assist with maintaining functional stability and contributes to day-to-day comfort during symptomatic periods.


Quick Fact: Relief for Key Symptoms
Upper Respiratory Sneezing, Runny Nose
Ocular Itchy, Watery Eyes
Dermatological Itching, Hives/Wheals

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Ap Loratadine?

Eligibility Category Status as Defined in Regulatory Labeling
Contraindicated Populations Individuals with documented hypersensitivity to Loratadine or any of the inactive ingredients (excipients) in the specific formulation. Certain formulations are also contraindicated for patients with specific hereditary disorders, such as Phenylketonuria (PKU) (for aspartame-containing products) or galactose intolerance (for lactose-containing tablets).
Conditional Use Populations Use requires caution and regulatory-specified modification in patients with severe hepatic impairment (liver disease) or severe renal impairment (kidney disease). Use in pregnancy and during breast-feeding is generally not recommended by regulatory bodies as a precautionary measure.
Age-Group Eligibility Use is officially established for children 2 years of age and older, with specific approved formulations based on age. The medicine is approved for use in adults and older adults. Safety and efficacy are not established in children under 2 years of age, and use in this group is not recommended.

Connection to the overall eligibility profile: Official drug labels define who can and cannot use Loratadine by classifying populations based on absolute prohibition, age-based restrictions, and the presence of underlying physiological conditions. These classifications mandate that the medicine either be avoided entirely, as in cases of drug hypersensitivity, or used only under conditions of special consideration, such as the required dose modification for severe liver or kidney disease.

Advertisements

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The official interaction profile for single-ingredient Loratadine is defined by its metabolic clearance and absorption kinetics, as documented in government regulatory labeling.


Pharmacokinetic Interactions

Loratadine is metabolized primarily by the Cytochrome P450 enzymes CYP3A4 and CYP2D6. Co-administration with certain inhibitors of these enzymes is formally documented to result in substantially increased plasma concentrations of Loratadine due to reduced clearance. Specific interacting medicines explicitly listed in regulatory documents include Ketoconazole, Erythromycin, and Cimetidine. Controlled clinical trials have indicated that these increases in exposure were without clinically significant changes (including electrocardiographic effects).


Food and Substance Interactions

  • Food: Ingestion of food is documented to increase the overall systemic bioavailability (AUC) of Loratadine by approximately 40–48% and to delay the time to maximum plasma concentration (Tmax).
  • Alcohol: Official regulatory studies have confirmed that Loratadine does not potentiate the effects of alcohol on psychomotor performance.

Population-Specific Considerations

No formal contraindications are listed for single-ingredient Loratadine based on drug-drug interactions. However, official labeling notes that reduced clearance in patients with severe hepatic impairment or renal impairment (GFR < 30 mL/min) is a necessary consideration due to the potential for increased exposure.

Advertisements

Mechanism of Action

Blocking Histamine H1 Receptors (Primary Action)

Ap Loratadine's active metabolite, desloratadine, acts as a selective inverse agonist/antagonist at peripheral Histamine H1 receptors ( H1 R). By binding to and stabilizing the inactive state of these receptors on cells in the skin, respiratory tract, and blood vessels, the drug effectively blocks the activating effects of naturally released histamine. This suppression of H1 signaling directly influences the physiological cascades that lead to altered vascular permeability and sensory nerve activation.


Suppressing Downstream Inflammatory Pathways

This also includes an H1 R-independent action involving the inhibition of key intracellular signaling proteins, such as Src and Syk kinases. By targeting these, the drug interferes with the activation of transcription factors like NF-kappa B ( Nuclear Factor kappa-light-chain-enhancer of activated B cells), thereby limiting the gene expression and synthesis of various pro-inflammatory cytokines and mediators. This influences cellular transcription in inflammatory pathways.


Modulating Core Physiological Responses

The suppression of H1 signaling and the inhibition of inflammatory proteins collectively adjust physiological function. These effects include reducing extravasation of plasma into tissues and decreasing H1 R-mediated sensory nerve activation. The collective result is an adjustment of excessive, mediator-driven physiological responses in peripheral tissues.

Advertisements

Dosage and Administration Information

Official Administration Guidelines

Ap Loratadine is authorized for oral administration across all labeled dosage forms, including the 10 mg tablet, the 5 mg/5 mL syrup, and the orally disintegrating tablet. The medicine is taken as a simple, once-daily regimen.


Population/Condition Dosing Schedule
Adults and Children 12 years and older 10 mg once daily
Children 2 to 5 Years 5 mg once daily (typically as oral solution)
Severe Hepatic Impairment 10 mg every other day (initial dose)

Procedural Instructions

The standard adult dose is one 10 mg unit taken once every 24 hours, and this maximum daily dose should not be exceeded. The oral formulations may be taken with or without food as the clinical effect remains consistent. The oral solution requires measurement using a dedicated dosing device to ensure accuracy, while orally disintegrating tablets should dissolve on the tongue.

If a dose is missed, it should be taken as soon as the oversight is remembered. However, if it is almost time for the next scheduled dose, the missed dose is skipped to maintain the once-daily frequency, and a double dose is not to be taken. Furthermore, the administration of Loratadine must be discontinued at least 48 hours prior to any allergy skin-prick testing, as the drug's activity may otherwise interfere with the testing results.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Ap Loratadine

Evidence for Use in Seasonal and Perennial Allergic Rhinitis (Hay Fever)

Research exploring Ap Loratadine for allergic rhinitis, which includes both seasonal (hay fever) and perennial forms, is primarily based on a large number of Randomized Controlled Trials (RCTs). These are the established type of study design where participants are randomly assigned to receive either the medicine or an inactive substitute (a placebo) to monitor how symptoms evolved during the observation periods. Many of these trials are also included in systematic reviews and meta-analyses, which are comprehensive studies that aggregate the findings of multiple individual trials.

These studies focused on documenting outcomes related to physical discomfort in the study populations. Researchers monitored changes in a Total Symptom Score (TSS) and specific symptoms, such as the frequency of sneezing and runny nose. The populations studied included adults, adolescents, and children across various age groups. The body of research reports observed patterns in the measured outcomes for most of these allergic rhinitis symptoms.


Evidence for Use in Chronic Urticaria (Hives)

Research for Ap Loratadine for use in chronic urticaria, a condition characterized by fluctuating manifestations of hives and itching, relies on Randomized Controlled Trials (RCTs). These trials were designed to document outcomes related to systemic or functional imbalance during the observation period.

Studies explored the suppression of the physical manifestations of the condition, specifically measuring the reduction in the number of visible wheals (hives) and the severity of pruritus (itching). Findings reported the measurements of symptom evolution in the observed populations during comparison against placebo over defined time intervals.


Evidence Quality, Limitations, and Areas for Further Research

The body of evidence for Ap Loratadine, particularly for allergic rhinitis, is characterized by numerous controlled studies and comprehensive meta-analyses. The evidence for chronic urticaria is also documented but often derived from smaller or more heterogeneous studies.

Key limitations noted by scientific reviews include the focus on short-term follow-up durations and the resulting limited information for long-term outcomes. Evidence is also limited regarding the effect on severe nasal congestion in rhinitis trials. The research describes how symptoms were monitored across various age groups, but the existing evidence base contains insufficient data for infants and children under the age of two.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Ap Loratadine (FAQ)


Q: Is Ap Loratadine available over the counter?

A: Yes, Ap Loratadine (Loratadine) is widely available in many regions as an Over-the-Counter (OTC) medicine, meaning it can be purchased without a prescription. This non-prescription availability is based on regulatory approval by agencies like the FDA for use by the general public.


Q: How long does it typically take for Ap Loratadine to start working?

A: According to official product information, the antihistamine effects are typically observed within 1 to 3 hours after administration. The maximum effectiveness, or peak effect, is generally achieved approximately 8 to 12 hours after a dose.


Q: Is Ap Loratadine suitable for long-term daily use?

A: Regulatory documents from bodies like the EMA have examined the effect of Ap Loratadine during long-term monitoring. These studies indicated there was no evidence of tolerance (where the drug loses effectiveness over time) to the antihistamine effect.


Q: Is it okay to take Ap Loratadine if I also take blood pressure medication?

A: Official drug information for single-ingredient Loratadine does not list interactions with blood pressure medications. However, combination products containing a decongestant (like pseudoephedrine) do require caution. For personalized safety guidance on combining medications, consulting a healthcare professional is consistent with official recommendations.


Q: Are there any specific foods that should be avoided while taking Ap Loratadine?

A: No specific foods are prohibited or required to be avoided. Official regulatory information notes that while food ingestion can increase the amount of medicine absorbed by the body (bioavailability), Ap Loratadine can be taken with or without food.


Q: What is the difference in action between Ap Loratadine and an older antihistamine like diphenhydramine?

A: Ap Loratadine is a second-generation antihistamine, which means it is chemically designed to be more selective for the body's peripheral histamine receptors. This design feature limits its ability to enter the brain, minimizing the sedative effects commonly seen with older, first-generation antihistamines.


Q: How long do the effects of Ap Loratadine usually last?

A: Studies noted in regulatory documents show that the antihistamine effects from a single dose last in excess of 24 hours. This duration of action is what supports the typical once-daily schedule.


Q: Is Ap Loratadine classified as a steroid?

A: No. Ap Loratadine is formally classified as a second-generation antihistamine. It functions as a selective peripheral H1-receptor antagonist to manage allergy symptoms and is not a steroid medication.


Q: Is there a generic version of Ap Loratadine?

A: Yes, the active ingredient, Loratadine, is widely available as a generic medication. This means that after the original patent expired, other manufacturers were approved to produce chemically equivalent versions.


Q: Can Ap Loratadine affect heart rhythm?

A: While regulatory documents list tachycardia (rapid heartbeat) and palpitation (fluttering) as very rare adverse reactions, official studies also indicate that Loratadine at recommended doses has practically no influence on the overall cardiovascular function.


Q: Why is Ap Loratadine sometimes combined with pseudoephedrine?

A: Ap Loratadine may be combined with pseudoephedrine in specific products. Pseudoephedrine is a decongestant ingredient that helps to relieve nasal congestion, which is a symptom that the antihistamine Loratadine alone may not fully address.


Q: What is Ap Loratadine’s safety classification in relation to driving or operating machinery?

A: Official regulatory documents state that Loratadine generally has no or negligible influence on a person’s ability to drive and use heavy machinery. This is consistent with its classification as a non-sedating antihistamine.


Q: Does Ap Loratadine cause changes in appetite or weight?

A: Regulatory documents list an increased appetite as a Common adverse reaction, meaning it has been observed in 1 out of every 10 to 100 patients. Changes in body weight itself are not specifically and commonly reported in the official safety profile.


Q: Does Ap Loratadine affect laboratory test results?

A: Yes, the activity of the drug can interfere with the results of allergy skin-prick testing. Regulatory warnings mandate that the medicine must be discontinued for at least 48 hours prior to having such tests performed.


Q: Is Ap Loratadine known to cause dry mouth?

A: Dry mouth is sometimes reported as an adverse reaction in regulatory documents. It is listed as a very rare side effect, meaning it is seen in less than 1 out of 10,000 patients who have used the medicine.


Q: Is Ap Loratadine effective against pet allergies?

A: Ap Loratadine is officially indicated to treat symptoms of allergic rhinitis (hay fever) and chronic urticaria (hives and itching). While pet dander is a frequent trigger for allergic rhinitis symptoms, the regulatory labels describe efficacy for the overall condition rather than specific allergens. For specific medical guidance, consult a healthcare professional.


Q: Is Ap Loratadine only for airborne allergens?

A: No. While the drug treats allergic rhinitis (which is often triggered by airborne allergens), it is also officially indicated for the treatment of chronic urticaria (hives and itching). Urticaria can be triggered by many factors that are not airborne.


Q: Do official documents mention any potential for long-term reliance on Ap Loratadine?

A: Studies noted in regulatory documents examined the effect of the medicine during long-term treatment. These findings indicated there was no evidence of tolerance to the antihistamine effect after continuous dosing over a defined period.


Q: Can Ap Loratadine make anxiety worse?

A: Official safety documents do not explicitly list anxiety. However, the related psychological effect of nervousness is listed as a Common adverse reaction in the pediatric population (children 2–12 years).

Advertisements

How should Ap Loratadine be stored and disposed of?

Official Storage and Disposal Requirements

Storage of Ap Loratadine must strictly adhere to regulatory guidelines to maintain potency and safety. Tablets and oral solutions should be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The product must be protected from excessive moisture and direct light.

Crucially, do not freeze the medicine, and avoid exposure to excessive heat. Always keep the product in its tightly closed, original container and ensure it remains out of the reach and sight of children to prevent accidental ingestion.

Disposal of unused or expired Loratadine should follow official guidance. Do not use the medicine past the expiration date. Utilize an official drug take-back program when available. If not, follow local protocols for household trash disposal, taking care to avoid releasing the medicine into the environment, such as down the sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ap Loratadine found in:

A-Z Index: